Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life
复制标题
DOI：
10.2169/internalmedicine.0091-17
复制
发表时间：
2018-01-01
影响因子：
1.2
通讯作者：
Koga, Akemi
中科院分区：
文献类型：
--
作者：
Kawakubo, Megumi;Eguchi, Yuichiro;Koga, Akemi
目的本研究的目的是确定daclatasvir (DCV) + asunaprevir （ASV）治疗24周是否会影响治疗开始后12周和24周的健康相关生活质量（HRQOL）。方法：本研究是一项前瞻性、纵向研究，比较接受DAA治疗的患者在治疗开始和EOT后12周的HRQOL与基线时的HRQOL。我们使用日本验证版的8项简短健康调查（SF-8）来评估患者的HRQOL。这个分数可以与日本的标准样本分数SF-8进行比较。采用Wilcoxon符号秩检验比较治疗前、治疗开始后12周和EOT时的HRQOL。我们招募了2014年11月至2015年7月在Saga大学医院接受24周DCV和ASV联合治疗HCV的患者。在死亡治疗期间因复发或不良反应而停止治疗的患者被排除在研究之外。结果两组患者SF-8量表、生理成分评分（PCS）和心理成分评分（MCS）在治疗期间均无显著变化。结论我们的研究对文献有重要贡献，因为DCV + ASV治疗24周的DAA治疗在治疗开始后12周或24周没有降低HRQOL。
Objective The aim of this study was to determine if direct-acting antiviral (DAA) treatment with daclatasvir (DCV) plus asunaprevir (ASV) for 24 weeks influenced the health-related quality of life (HRQOL) at 12 and 24 weeks after treatment initiation [end of treatment (EOT)].Methods This was a prospective, longitudinal study comparing the HRQOL of patients receiving DAA treatment at 12 weeks after treatment initiation and EOT with the HRQOL at baseline. We used a Japanese-validated version of the 8-item Short Form Health Survey (SF-8) to assess the HRQOL of patients. This score can be compared to the Japanese normative sample scores of SF-8. Wilcoxon signed-rank tests were used to compare the HRQOL before treatment, 12 weeks after treatment initiation, and at EOT.Patients We enrolled patients who received 24-week combination therapy using DCV and ASV for HCV at Saga University Hospital between November 2014 and July 2015. Those who discontinued treatment due to relapse or adverse reactions during die treatment period were excluded from the study.Results There were no significant changes in any of the SF-8 subscales, Physical component scores(PCS) or mental component scores(MCS)during the treatment period for both males and females.Conclusion Our study makes a significant contribution to the literature because 24-week DAA treatment with DCV plus ASV did not decrease the HRQOL at 12 or 24 weeks after treatment initiation.